May 5 |
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
|
May 5 |
Wall Street Breakfast: The Week Ahead
|
May 2 |
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
|
May 1 |
Editas, Bristol Myers extend T cell therapy collaboration
|
May 1 |
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
|
Apr 29 |
12 Under-the-Radar Stocks With Massive Upside for 2024
|
Apr 26 |
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
|
Apr 22 |
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
|